Shares of Scholar Rock SRRK.O rise 9.69% to $52.51 premarket
Q2 net loss per share was $0.84 vs loss of $0.98 per share last year
Up to last close, stock up ~9% YTD
FDA review and launch preparation continue
Co says FDA review of the application of its spinal muscular atrophy drug continues to advance with two fill-finish facilities, representing two independent paths to a decision by September 30
Adds co is prepared for U.S. launch of the drug, apitegromab, immediately upon FDA approval; ample supply available for commercialization
As of June 30, 2026, SRRK had cash, cash equivalents, and marketable securities of $492.1 million
SRRK•
